Literature DB >> 34309397

Type II Fatty Acid Synthesis Pathway and Cyclopropane Ring Formation Are Dispensable during Enterococcus faecalis Systemic Infection.

Claire Poyart1,2,3, Agnes Fouet1,2, Constantin Hays1,2,3, Clara Lambert1, Sophie Brinster1, Gilles Lamberet4, Laurence du Merle5,6, Karine Gloux4, Alexandra Gruss4.   

Abstract

Enterococcus faecalis, a multiple antibiotic-resistant Gram-positive bacterium, has emerged as a serious nosocomial pathogen. Here, we used a genetic approach to characterize the strategies used by E. faecalis to fulfill its requirements for endogenous fatty acid (FA) synthesis in vitro and in vivo. The type II fatty acid synthesis (FASII) pathway is encoded by two operons and two monocistronic genes. Expression of all of these genes is repressed by exogenous FAs, which are incorporated into the E. faecalis membrane and modify its composition. Deletion of nine genes of the 12-gene operon abolished growth in an FA-free medium. Addition of serum, which is lipid rich, restored growth. Interestingly, the E. faecalis membrane contains cyclic fatty acids that modify membrane properties but that are unavailable in host serum. The cfa gene that encodes the cyclopropanation process is located in a locus independent of the FASII genes. Its deletion did not alter growth under the conditions tested, but yielded bacteria devoid of cyclic FAs. No differences were observed between mice infected with wild-type (WT) or with FASII or cyclopropanation mutant strains, in terms of bacterial loads in blood, liver, spleen, or kidneys. We conclude that in E. faecalis, neither FASII nor cyclopropanation enzymes are suitable antibiotic targets. IMPORTANCE Membrane lipid homeostasis is crucial for bacterial physiology, adaptation, and virulence. Fatty acids are constituents of the phospholipids that are essential membrane components. Most bacteria incorporate exogenous fatty acids into their membranes. Enterococcus faecalis has emerged as a serious nosocomial pathogen that is responsible for urinary tract infections, bacteremia, and endocarditis and is intrinsically resistant to numerous antibiotics. E. faecalis synthesizes saturated and unsaturated fatty acids, as well as cyclic fatty acids that are not found in the human host. Here, we characterized mutant strains deficient in fatty acid synthesis and modification using genetic, biochemical, and in vivo approaches. We conclude that neither the fatty acid synthesis pathway nor the cyclopropanation enzyme are suitable targets for E. faecalis antibiotic development.

Entities:  

Keywords:  Enterococcus faecalis; FASII pathway; antibiotic target; cyclopropane ring formation; fatty acids; septicemic infection

Mesh:

Substances:

Year:  2021        PMID: 34309397      PMCID: PMC8459760          DOI: 10.1128/JB.00221-21

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  46 in total

Review 1.  Missing genes in metabolic pathways: a comparative genomics approach.

Authors:  Andrei Osterman; Ross Overbeek
Journal:  Curr Opin Chem Biol       Date:  2003-04       Impact factor: 8.822

Review 2.  Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?

Authors:  Joshua B Parsons; Charles O Rock
Journal:  Curr Opin Microbiol       Date:  2011-08-20       Impact factor: 7.934

3.  Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments.

Authors:  Gérald Kénanian; Claire Morvan; Antonin Weckel; Amit Pathania; Jamila Anba-Mondoloni; David Halpern; Marine Gaillard; Audrey Solgadi; Laetitia Dupont; Céline Henry; Claire Poyart; Agnès Fouet; Gilles Lamberet; Karine Gloux; Alexandra Gruss
Journal:  Cell Rep       Date:  2019-12-17       Impact factor: 9.423

Review 4.  Exogenous fatty acid metabolism in bacteria.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochimie       Date:  2017-06-28       Impact factor: 4.079

Review 5.  Nosocomial bloodstream infections: organisms, risk factors, and implications.

Authors:  A W Karchmer
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

6.  A ring to rule them all: the effect of cyclopropane Fatty acids on the fluidity of lipid bilayers.

Authors:  David Poger; Alan E Mark
Journal:  J Phys Chem B       Date:  2015-04-16       Impact factor: 2.991

7.  Intravenous mouse infection model for studying the pathology of Enterococcus faecalis infections.

Authors:  Claudia Gentry-Weeks; Monica Estay; Cindy Loui; Dale Baker
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

8.  A novel synthesis of trans-unsaturated fatty acids by the Gram-positive commensal bacterium Enterococcus faecalis FA2-2.

Authors:  Tatiana Kondakova; Sneha Kumar; John E Cronan
Journal:  Chem Phys Lipids       Date:  2019-05-02       Impact factor: 3.329

9.  Lipid and fatty acid composition of organs from copper-deficient mice.

Authors:  S C Cunnane; K R McAdoo; J R Prohaska
Journal:  J Nutr       Date:  1986-07       Impact factor: 4.798

10.  Enterococcus faecalis Encodes an Atypical Auxiliary Acyl Carrier Protein Required for Efficient Regulation of Fatty Acid Synthesis by Exogenous Fatty Acids.

Authors:  Lei Zhu; Qi Zou; Xinyun Cao; John E Cronan
Journal:  mBio       Date:  2019-05-07       Impact factor: 7.867

View more
  3 in total

Review 1.  FabT, a Bacterial Transcriptional Repressor That Limits Futile Fatty Acid Biosynthesis.

Authors:  Alexandra Gruss; Agnes Fouet; Clara Lambert; Claire Poyart
Journal:  Microbiol Mol Biol Rev       Date:  2022-06-21       Impact factor: 13.044

Review 2.  Advances in the Structural Biology, Mechanism, and Physiology of Cyclopropane Fatty Acid Modifications of Bacterial Membranes.

Authors:  John E Cronan; Tiit Luk
Journal:  Microbiol Mol Biol Rev       Date:  2022-04-18       Impact factor: 13.044

3.  The Enterococcus faecalis FabT Transcription Factor Regulates Fatty Acid Biosynthesis in Response to Exogeneous Fatty Acids.

Authors:  Qi Zou; Huijuan Dong; Lei Zhu; John E Cronan
Journal:  Front Microbiol       Date:  2022-04-25       Impact factor: 6.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.